Taysha Gene Therapies, Inc.
TSHA
$2.31
-$0.07-2.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 13.85% | 13.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.85% | 13.09% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 13.85% | 13.09% | |||
| SG&A Expenses | 102.58% | -54.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.06% | -3.91% | |||
| Operating Income | -7.47% | 5.36% | |||
| Income Before Tax | -14.61% | 26.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -14.61% | 26.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.61% | 26.40% | |||
| EBIT | -7.47% | 5.36% | |||
| EBITDA | -7.69% | 5.48% | |||
| EPS Basic | -14.14% | 26.55% | |||
| Normalized Basic EPS | -40.18% | 31.47% | |||
| EPS Diluted | -14.14% | 26.55% | |||
| Normalized Diluted EPS | -40.18% | 31.47% | |||
| Average Basic Shares Outstanding | 0.34% | 0.21% | |||
| Average Diluted Shares Outstanding | 0.34% | 0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||